Cardio-Cerebral And Peripheral Vascular Health

Cardiovascular and cerebrovascular diseases are the top killers of human health. According to the data, the number of these patients in the world reached 523 million in 2019. About 330 million people in China suffer from them, and the mortality accounts for 40% of overall mortality in the residents. In addition to the risk of death, the high incidence and disability rate of cardiovascular disease bring heavy economic and psychological burden to society, families and patients
Tide Pharmaceutical has China's first international high-end lipid microsphere carrier targeted drug “Alprostadil Injection” - “Kaishi   and oral prostacyclin (PGI2) derivatives - Kaina   ”, which can effectively treat cardiovascular, cerebrovascular and peripheral vascular diseases and improve clinical symptoms and prognosis through multiple pharmacological effects such as dilating blood vessels as well as improving circulation and anti-platelet aggregation.

Kaina    (Beraprost Sodium Tablets)

Kaishi    (Alprostadil Injection)

NAME OF THE DRUG
【GENERIC NAME】: Beraprost Sodium Tablets
【TRADE NAME】:Kaina

【Indications】
To improve ulcers, intermittent claudication, pain, cold sensation and other symptoms caused by chronic arterial occlusive disease.
【Description】
This product of 20 µg is white to off-white film-coated tablet, engraved with "BS20" on one side, which is white after removing the coating; this product of 40 µg is yellowish film-coated tablet, engraved with "BS40" on one side, which is white after removing the coating.
【Strength】
(1) 20 µg; (2) 40 µg
【Dosage and Administration】
Usually, adults take it orally after meals. 40 μg at a time, three times a day.

NAME OF THE DRUG
【GENERIC NAME】: Alprostadil Injection
【TRADE NAME】:Kaishi

【Indications】

1. To treat limb ulcers caused by chronic arterial occlusion (thromboangiitis obliterans, occlusive arteriosclerosis, etc.) and rest pain in the limbs caused by microvascular circulation disorders, and improve microcirculation disturbance of cardio cerebral vessels.

2. To inhibit intravascular thrombosis after transplantation as antithrombotic therapy after organ transplantation.

3. To relieve hypoxemia and maintain catheter blood flow before surgical treatment of arterial catheter-dependent congenital heart disease.

4. Adjuvant therapy of chronic hepatitis.
【Description】
This product is white emulsion liquid.
【Strength】
(1) 1ml: 5 μg  (2) 2 ml: 10 μg.
【Dosage and Administration】
Once a day for adults, by slow intravenous injection of 1-2 ml (5-10 μg of alprostadil) + 10 ml of normal saline (or 5% glucose) or by slow intravenous drip infusion through Murphy’s dropper.

®

®

®

®